Yep. In a situation like this, the government needs to move very quickly and make fast decisions. Do you think they’re going to go with a known quantity like Gilead, or go with an unknown company that doesn’t even have a drug on the market right now? Zero chance they take that risk of having egg on their face after already being accused of being behind the eight ball with this whole process.
It feels to me like our strategy is schizophrenic. Chasing 25 indications is great for Pfizer or Merck, but for a company made up of less than 10 people and no money in the bank, I struggle to see why we don’t just get one thing done at a time.